The efficacy of bypassing agents in surgery of hemophilia patients with inhibitors

BACKGROUND: Inhibitory antibodies to factor VIII (FVIII) or IX (FIX) are important issues when managing patients with hemophilia A or B. Advances in bypassing agents such as recombinant activated FVII (rFVIIa) and activated prothrombin complex concentrates (APCC) have enabled the aggressive manageme...

Descripción completa

Detalles Bibliográficos
Autores principales: Ju, Hee Young, Jang, Hye Lim, Park, Young Shil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4595584/
https://www.ncbi.nlm.nih.gov/pubmed/26457285
http://dx.doi.org/10.5045/br.2015.50.3.173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4595584/
https://www.ncbi.nlm.nih.gov/pubmed/26457285
http://dx.doi.org/10.5045/br.2015.50.3.173

Ejemplares similares